| Literature DB >> 26558050 |
Abstract
OBJECTIVES: To evaluate a supracostal approach for percutaneous nephrolithotomy (PCNL) of staghorn calculi through a prospective study and review of previously reported cases.Entities:
Keywords: Percutaneous; Pleura; S-PCNL, (supracostal) percutaneous nephrolithotomy; Staghorn calculi; Supracostal
Year: 2012 PMID: 26558050 PMCID: PMC4442912 DOI: 10.1016/j.aju.2012.08.001
Source DB: PubMed Journal: Arab J Urol ISSN: 2090-598X
Figure 1(a) Landmarks relevant to supracostal access: PSL, paraspinal line; MSL, midscapular line; PAL, posterior axillary line. A small needle points to the upper calyx. The puncture for a supra-12th rib approach at the MSL is in the middle of the intercostal space. (b) The nephrostomy tube placed at conclusion of the procedure.
The univariate analysis of factors affecting the stone-free rate after initial S-PCNL.
| Characteristic | Stone-free, | Residual stones, | |
|---|---|---|---|
| No. of patients | 26 | 14 | |
| 43.5 (10.4) | 42.9 (13.5) | 0.860 | |
| 0.736 | |||
| No | 15 | 10 | |
| Obese | 11 | 4 | |
| 0.720 | |||
| Male | 19 | 9 | |
| Female | 7 | 5 | |
| 1 | |||
| No | 25 | 13 | |
| Yes | 1 | 1 | |
| Side | 0.186 | ||
| Left | 14 | 4 | |
| Right | 12 | 10 | |
| 0.006 | |||
| Partial | 20 | 4 | |
| Complete | 6 | 10 | |
| 1 | |||
| Opaque | 25 | 13 | |
| Lucent | 1 | 1 | |
| 0.52 | |||
| One | 16 | 7 | |
| Two | 10 | 7 | |
| 0.085 | |||
| 90–140 | 20 | 7 | |
| 141–180 | 6 | 7 | |
| 0.705 | |||
| No | 19 | 6 | |
| Yes | 7 | 8 | |
Body mass index classification, normal weight <24; overweight, 24–<28 and obese, ⩾28 kg/m2.
Access; one, supracostal only; two, supracostal + additional access through middle or lower calyx.
Complications of S-PCNL in 40 patients classified according to the modified Clavien system [6].
| Grade | Clavien definition | Complication, |
|---|---|---|
| 1 | Any deviation from normal postoperative course with no need for pharmacological treatment or surgical, endoscopic, and radiological interventions. Allowed therapeutic regimens are drugs as anti-emetics, antipyretics, analgesics, diuretics, electrolytes, and physiotherapy. | Urine leakage managed by watchful waiting, 1 (2.5) |
| 2 | Complications requiring pharmacological treatment with drugs other than such allowed for grade 1 complications | Blood transfusion, 4(10) |
| 3a | Complications requiring surgical, endoscopic, or radiological intervention not under general anaesthesia | JJ stent placement for urine leakage >24 h, 2(5) |
| Renal pelvic perforation, 1(2.5) | ||
| Urinoma, 1(2.5) | ||
| Hydrothorax, 4(10) | ||
| Pseudoaneurysm, 1(2.5) | ||
| 3b | Complications requiring surgical, endoscopic, or radiological intervention under general anaesthesia | Nil |
| 4a | Life-threatening complications requiring intensive management; single organ dysfunction | Nil |
| 4b | Life-threatening complications requiring intensive management; multi-organ dysfunction | Nil |
| 5 | Death of the patient | Nil |
Univariate analysis of factors affecting complications after S-PCNL.
| Factor | Complications, | ||
|---|---|---|---|
| No | Yes | ||
| 90–140 | 23 | 4 | <0.001 |
| 141–180 | 2 | 11 | |
| Male | 19 | 9 | 0.311 |
| Female | 6 | 6 | |
| No | 16 | 9 | 1 |
| Yes | 9 | 6 | |
| Left | 11 | 7 | 1 |
| Right | 14 | 8 | |
| No | 24 | 14 | 1 |
| Yes | 1 | 1 | |
| Complete | 4 | 12 | <0.001 |
| Partial | 21 | 3 | |
| Two | 8 | 9 | 0.107 |
| One | 17 | 6 | |
Stepwise regression analysis of predictors of the stone-free rate and complications after S-PCNL.
| Factors affecting | Regression coefficient | Relative risk (95% CI) | |
|---|---|---|---|
| Staghorn stone burden | 2.120 | 8.333(1.906–36.440) | 0.005 |
| Constant | −1.609 | 0.200 | 0.003 |
| Operative duration (min) | 1.905 | 6.719(1.047–43.123) | 0.045 |
| Staghorn stone burden | 2.465 | 11.758(1.981–69.793) | 0.007 |
| Constant | −2.350 | 0.095 | 0.001 |
A summary of supracostal procedures in previously published studies
| Ref. | TS | Np | Nss | AA | SFR | AP† | OC | PC | Pn | H/H | RPF | BT | OD (min) | HS (days) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RS | 115 | 108 (93.9) | 23 (20) | 78 (67.8) | 53 (46) | 30 (26.1) | 4 (3.5) | 0 | 4 (3.5) | 0 | 20 (17.4) | 185(60–410) | 8.5(4–23) | |
| CRS | 98 | 41 (41.8) | ND | ND | ND | 16 (16.3) | 7 (7.1) | 1 (1) | 4 (4.1) | 2 (2) | 4 (4.1) | ND | ND | |
| RS | 102 | 20 (19.6) | ND | 81 (79.5) | ND | 10 (9.8) | 10 (9.8) | 1 (1) | 9 (8.8) | 0 | 0 | ND | ND | |
| RS | 103 | 103 (100) | 42 (40.7) | 54 (52.5) | 48 (47) | 29 (28.2) | 6 (5.8) | 0 | 6 (5.8) | 0 | 17 (16) | ND | ND | |
| RS | 35 | 35 (100) | 0 | 33 (94) | 17 (48) | 9 (25.7) | 1 (2.8) | 0 | 1 (2.8) | 0 | ND | 174(120–210) | 2(1–10) | |
| PS | 62 | 26 (41.9) | 15 (23.8) | 57 (90) | 13 (20.6) | 14 (22.2) | 7 (11) | 0 | 7 (11) | 0 | 6 (9.5) | ND | 5.25 | |
| CRS | 332 | 127 (38.2) | 155 (46) | ND | ND | 74 (22.2) | 11 (3.3) | 0 | 11 (3.3) | 0 | 6 (1.8) | ND | ND | |
| PS | 110 | 32 (29) | 9 (8.2) | 95 (86.4) | 15 (13.6) | 13 (11.8) | 10 (9.1) | 0 | 10 (9.1) | 0 | 2 (1.8) | ND | 5.3(2–15) | |
| CPS | 103 | 49 (47.5) | ND | 91 (88) | ND | 11 (10.7) | 1 (1) | 0 | 1 (1) | 0 | 7 (6.8) | 95 | ND | |
| PS | 30 | 11 (37) | 11 (37) | 24 (89) | 3 (11) | 4 (13) | 2 (7) | 0 | 1 (3) | 1 (3) | 1 (3) | 66.4(45–120) | 3.7(2-10) | |
| CRS | 123 | 31 (25) | 31 (25) | 110 (89.4) | 10 (8) | 16 (13) | 3 (2.4) | 3 (2.4) | 0 | 0 | 7 (6) | 92 ± 37 | 2 (2–7) | |
| CRS | 154 | 51 (33.3) | 10 (6.5) | 132 (89.9) | 23 (14.9) | 23 (14. 9) | 5 (3.2) | 0 | 5 (3.2) | 0 | 0 | ND | 2.5 | |
| CRS | 144 | 29 (20.1) | 22 (15.3) | 127 (88.2) | 5 (3.5) | 19 (13.2) | 5 (3.5) | 0 | 5 (3.5) | 0 | 7 (4.9) | ND | 34.13 (h) | |
| CPS | 95 | 29 (30.5) | 0 | 84 (87.6) | ND | 9 (9.5) | 9 (9.5) | 0 | 9 (9.5) | 0 | 0 | 58.85(30–105) | 4.8(3–10) | |
| CPS | 170 | 48 (28.2) | 0 | 140 (82.4) | 6 (3.5) | 31 (18.2) | 26 (15. 3) | 0 | 26 (15.3) | 0 | 4 (2.4) | 70.9(30–240) | 4.45(2–13) | |
| Present study | PS | 40 | 40 (100) | 17 (42) | 31 (78) | 14 (35) | 15 (38) | 4 (10) | 0 | 4 (10) | 0 | 4 (10) | 120(90–180) | 6.8(3–12) |
Data are n (%), except TS, Np, OD and HS. RS, retrospective; CRS, comparative retrospective; PS, prospective; CPS, comparative prospective; ND, not defined; †Includes ESWL, second-look nephroscopy, ureteroscopy, JJ stent. TS, type of study; Np, n patients; Nss, n staghorn stones; AA, additional access; SFR, stone-free rate; AP, auxiliary procedures; OC, overall complications; PC, pleural complications; Pn, pneumothorax; H/H, haemo/hydrothorax; RPF, reno-pleural fistula; BT, blood transfusion; OD, operative duration, as mean (range); HS, hospital stay, as mean (range).